Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Allogene Therapeutics Inc
(NQ:
ALLO
)
2.410
-0.100 (-3.98%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Allogene Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
The Latest Analyst Ratings for Allogene Therapeutics
May 04, 2023
Via
Benzinga
Recap: Allogene Therapeutics Q1 Earnings
May 03, 2023
Via
Benzinga
Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update
May 03, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
April 26, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Xerox, Hubbell, Spotify And Other Big Stocks Moving Higher On Tuesday
April 25, 2023
U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Where Allogene Therapeutics Stands With Analysts
April 18, 2023
Via
Benzinga
10 Analysts Have This to Say About Allogene Therapeutics
March 21, 2023
Via
Benzinga
Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023
April 25, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer
April 20, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting
April 17, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics's Return On Capital Employed Insights
March 03, 2023
Via
Benzinga
What 10 Analyst Ratings Have To Say About Allogene Therapeutics
March 02, 2023
Via
Benzinga
7 Short-Squeeze Stocks That Could Make You Rich
April 13, 2023
Although moving against the grain presents its own distinct set of risks, these short-squeeze stocks may profit the contrarian.
Via
InvestorPlace
Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday
April 13, 2023
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences
April 13, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
7 Short-Squeeze Stocks That Could Explode in April
March 30, 2023
Although these short-squeeze stocks attracted bearish attention justifiably, contrarian sentiment may see them jump higher.
Via
InvestorPlace
Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report
March 30, 2023
Report Highlights Company’s Mission to Democratize Patient Access to CAR T While Maintaining Focus on Employee Engagement, Sustainability and Corporate Governance
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Short Interest Update - Monday, March 27
March 27, 2023
Although equities broadly are starting the new week higher, the most heavily shorted stocks are trading lower today.
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
March 21, 2023
Via
Benzinga
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting
March 14, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
March 08, 2023
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Via
News Direct
Topics
Economy
Exposures
Supply Chain
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
March 08, 2023
By David Willey, Benzinga
Via
TheNewswire.com
Topics
Economy
Exposures
Supply Chain
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
March 07, 2023
Cryoport Inc. (NASDAQ: CYRX) provides the life sciences industry with comprehensive supply chain solutions to support vital therapeutics.
Via
Benzinga
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
March 02, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy
March 01, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 28, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023
February 21, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Short Squeezes Have Returned in 2023 -- Here's Your Playbook
February 08, 2023
We haven't seen moves like these in a couple of years, so here's what investors should know.
Via
The Motley Fool
Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology
February 01, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
January 25, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.